BASF India Ltd
BASFBASF India Ltd's stock has fallen further than its earnings. EPS fell 12.3% in a year while the price moved −20.7%.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is in a downtrend (57 weeks in) while the P/E sits at the 0th percentile of its own 6-year range. Underneath, the last four quarters read improving — profit +162.8% year on year, and 73% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
BASF India Ltd trades at ₹3,662, in a downtrend and 57 weeks into that stage. That is −4.8% against its own 200-day average. It sits at 32% of a 52-week range of ₹3,286 to ₹4,462. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a downtrend — week 57 of stage 4, confirmed. At ₹3,662 it trades −4.8% versus its 200-day average and sits at 32% of its 52-week range (₹3,286–₹4,462).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +373% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-09-04) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
BASF India Ltd trades at 25.7× P/E, about the cheapest it has ever traded. Its long-run median P/E is 50.8×, measured across 5.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 25.7× is about the cheapest it has ever traded, against a long-run median of 50.8× measured over 5.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −12.3% against a −20.7% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +1.4%/yr price move, ~+23.5%/yr came from earnings growth and ~−22.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, BASF India Ltd was paying for profit growth of about 21.3% a year. Profit itself has compounded 11.8% a year over the past 20 years. Today the market pays 25.7× P/E, the 0th percentile of its own 6-year range.
What the two numbers say together. The multiple is low against its own past, and the growth the price is paying for is above what this company has actually delivered. A multiple that looks low because earnings fell is not the same thing as a low bar to clear.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
BASF India Ltd reads as turning around on its fundamental arc. Turning around — EPS growth swung from −42.2% at the trough to +62.4%, a 2-quarter improving streak, ROCE holding at 14.6%. The read is built from 10 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +1.1% | — | — | — |
| Profit | −12.3% | — | — | — |
| EPS | −12.3% | — | — | — |
| Share price | −20.7% | +9.1% | +1.4% | +12.5% |
4-Factor Sector Score
52.7/100 — rank 9 of 20 in Chemicals - Organic · 94% evidence confidence
BASF India Ltd scores 52.7 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 9. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 20 + 10.7 + 14.3 + 7.7 = 52.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
BASF India Ltd reported ₹4,824 Cr of revenue in the Jun 26 quarter, +24.5% year on year. That is the 3rd straight quarter of year-on-year growth. Over 20 years it has compounded at 16.7% a year. The last full year, FY26, came in at ₹14,944 Cr. The last four reported quarters add to ₹16,027 Cr.
FY26 revenue came in at ₹14,944 Cr (+1.1% on the year), capping 20 years at 16.7% compound. The latest quarter (Jun 26) printed ₹4,824 Cr, +24.5% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +6.8% growth against the decade's 16.7% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +6.5% over the last 4 quarters against +10.4%/yr over the last 8 — rolling over; TTM profit +62.4% vs +0.5%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
BASF India Ltd's operating margin is 10.0% in the Jun 26 quarter, +4.0 percentage points against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 3.7% to 13.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 10.0%, +4.0 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 3.7%–13.0%.
Why the margin moved: operating margin went +4.9 pp year on year while gross margin went +2.6 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
BASF India Ltd earned ₹360 Cr of net profit in the Jun 26 quarter, +162.8% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹420 Cr. The 20-year compound rate is 11.8%. That is 7.5% of the quarter's revenue. The same quarter a year earlier earned ₹137 Cr.
Jun 26 profit was ₹360 Cr, +162.8% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹420 Cr (−12.3%), and the 20-year compound rate is 11.8%.
Why profit moved: revenue contributed +24.5% and the margin +4.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +76.2% vs revenue +6.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 73% of BASF India Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹−110 Cr of operating cash against ₹420 Cr of profit. After ₹156 Cr of capital spending, ₹−266 Cr was left as free cash.
FY26: operating cash of ₹−110 Cr against reported profit of ₹420 Cr, leaving free cash of ₹−266 Cr after ₹156 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 73% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 73%: the cash cycle tightened 20 days between FY08 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
BASF India Ltd's cash conversion cycle runs 40 days in FY26, down from 60 days in FY08. Capital spending ran ₹513 Cr over the last 3 years. At FY26 sales of ₹14,944 Cr each day of that cycle holds about ₹40.9 Cr, so roughly ₹1,638 Cr sits inside the business at any moment.
FY26: debtors at 67 days, inventory at 77 days — roughly 2.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 40 days, tighter than FY08's 60.
The full loop: cash goes out to suppliers and production on day 0; stock waits 77 days to sell; customers pay about 67 days after that; and suppliers themselves are paid at 104 days — netting out to the 40-day cycle.
In money terms: at FY26 sales of ₹14,944 Cr, each day of the cycle holds about ₹40.9 Cr — so the 40-day loop keeps roughly ₹1,638 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹513 Cr over the last 3 fiscal years against ₹343 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹160 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
BASF India Ltd earns a ROCE of 15% in FY26. Return on invested capital clears the cost of that capital by +7.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 2.8% net margin on 1.77× asset turns.
FY26 ROCE is 15%.
Why the return is what it is — the wiring (FY26): 2.8% net margin × 1.77× asset turns × 2.13× balance-sheet leverage ≈ 10.6% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 19.2% − 12.0% = a +7.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
BASF India Ltd carries total debt of ₹133 Cr against shareholder equity of ₹3,957 Cr as of Mar 26, a debt-to-equity of 0.03 — effectively unlevered. On the annual view that ratio went from 0.05 in FY22 to 0.03 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹133 Cr against shareholder equity of ₹3,957 Cr — a debt-to-equity of 0.03. On the annual view, debt-to-equity went from 0.05 (FY22) to 0.03 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of BASF India Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.3 points over the same window, to 6.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +0.9 points over 8 quarters to 5.2%; Domestic institutions: +0.3 points over 8 quarters to 6.3%; Promoters: +0.0 points over 8 quarters to 73.3%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
BASF India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Valiant Organics LtdVALIANTORG | 63.2/100Mixed-positive evidence87% evidence | TURNING | 24.4/35 Revenue 1.5% · PAT 100% · OPM change 6 pp 95% evidence | 10.8/25 ROCE 5.5% · OPM 18% 95% evidence | 11.0/20 P/E 22× · PEG — 50% evidence | 17.0/20 RS sector 9.4% · RS bench 42.8% · 1Y 9.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 10.8 + 11 + 17 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Foseco India LtdFOSECOIND | 63.1/100Mixed-positive evidence87% evidence | BREAKING OUT | 19.5/35 Revenue 32.6% · PAT 20.5% · OPM change 5.2 pp 100% evidence | 16.9/25 ROCE 17.4% · OPM 23% 100% evidence | 11.5/20 P/E 44.8× · PEG 1.31 65% evidence | 15.2/20 RS sector 24.1% · RS bench 21% · 1Y -4%6 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 16.9 + 11.5 + 15.2 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Elantas Beck India LtdELANTAS | 62.3/100Mixed-positive evidence76% evidence | BREAKING OUT | 26.3/35 Revenue 17.6% · PAT 33.1% · OPM change 10 pp 95% evidence | 19.1/25 ROCE 21.2% · OPM 29% 76% evidence | 6.3/20 P/E 64.8× · PEG — 50% evidence | 10.6/20 RS sector -6.6% · RS bench 52.4% · 1Y 35.2%6 of 9 weeks ahead 70% evidence |
| Exact sum: 26.3 + 19.1 + 6.3 + 10.6 = 62.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 4OCCL LtdOCCLLTD | 61.4/100Mixed-positive evidence60% evidence | BREAKING OUT | 26.5/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.2/25 ROCE 13% · OPM 28% 76% evidence | 11.5/20 P/E 10.4× · PEG — 15% evidence | 11.2/20 RS sector — · RS bench 41.5% · 1Y —9 of 9 weeks ahead 25% evidence |
| Exact sum: 26.5 + 12.2 + 11.5 + 11.2 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shri Ahimsa Naturals LtdSHRIAHIMSA | 61.0/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 18.0/25 ROCE 21.7% · OPM 28% 95% evidence | 10.0/20 P/E 37.2× · PEG — 15% evidence | 14.1/20 RS sector 22.9% · RS bench 58.3% · 1Y 113%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 18 + 10 + 14.1 = 61 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Indo Amines LtdINDOAMIN | 60.6/100Mixed-positive evidence81% evidence | BASING | 22.3/35 Revenue 13.3% · PAT 24.2% · OPM change 3 pp 95% evidence | 16.8/25 ROCE 19.9% · OPM 14% 95% evidence | 14.0/20 P/E 11.3× · PEG — 50% evidence | 7.5/20 RS sector -11.9% · RS bench 4.6% · 1Y -12.6%4 of 10 weeks ahead 70% evidence |
| Exact sum: 22.3 + 16.8 + 14 + 7.5 = 60.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Balaji Amines LtdBALAMINES | 59.3/100Mixed-positive evidence82% evidence | LEADER | 26.4/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.3/25 ROCE 11% · OPM 25% 76% evidence | 7.0/20 P/E 36.1× · PEG — 50% evidence | 12.6/20 RS sector 18.3% · RS bench 51.3% · 1Y 53.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.3 + 7 + 12.6 = 59.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Nitta Gelatin India LtdNITTAGELA | 59.2/100Mixed-positive evidence72% evidence | TURNING | 18.8/35 Revenue 10.5% · PAT 24.1% · OPM change 4 pp 95% evidence | 19.1/25 ROCE 27.7% · OPM 24% 95% evidence | 9.7/20 P/E 14.4× · PEG — 50% evidence | 11.6/20 RS sector — · RS bench 46.7% · 1Y —7 of 9 weeks ahead 25% evidence |
| Exact sum: 18.8 + 19.1 + 9.7 + 11.6 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9BASF India Ltdthis pageBASF | 52.7/100Mixed-positive evidence94% evidence | BREAKING OUT | 20.0/35 Revenue 6.5% · PAT 62.4% · OPM change 4 pp 100% evidence | 10.7/25 ROCE 14.5% · OPM 10% 100% evidence | 14.3/20 P/E 25.7× · PEG 1.62 100% evidence | 7.7/20 RS sector -3.3% · RS bench -3.4% · 1Y -21.2%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20 + 10.7 + 14.3 + 7.7 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10GFL LtdGFLLIMITED | 51.5/100Mixed-positive evidence72% evidence | BREAKING OUT | 23.9/35 Revenue 10.5% · PAT 100% · OPM change 1064 pp 71% evidence | 7.8/25 ROCE 2.1% · OPM 28.2% 95% evidence | 11.3/20 P/E 10.6× · PEG — 15% evidence | 8.5/20 RS sector -14% · RS bench 12.9% · 1Y -2.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 7.8 + 11.3 + 8.5 = 51.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Laxmi Organic Industries LtdLXCHEM | 49.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 19.9/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.4/25 ROCE 4.7% · OPM 12% 100% evidence | 14.7/20 P/E 38.8× · PEG 1.14 100% evidence | 6.5/20 RS sector -19.5% · RS bench 9.7% · 1Y -16.6%9 of 10 weeks ahead 70% evidence |
| Exact sum: 19.9 + 8.4 + 14.7 + 6.5 = 49.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries LtdFINEORG | 45.6/100Mixed-negative evidence100% evidence | BREAKING OUT | 14.8/35 Revenue 7.1% · PAT 5.8% · OPM change 4 pp 100% evidence | 17.6/25 ROCE 21.5% · OPM 25% 100% evidence | 7.2/20 P/E 36.2× · PEG 2.7 100% evidence | 6.0/20 RS sector -13.8% · RS bench 12.9% · 1Y 7.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 17.6 + 7.2 + 6 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Jyoti Resins and Adhesives LtdJYOTIRES | 43.1/100Mixed-negative evidence69% evidence | 9.7/35 Revenue 12.8% · PAT -11.1% · OPM change -13 pp 95% evidence | 19.2/25 ROCE 36.5% · OPM 14% 76% evidence | 10.8/20 P/E 16.2× · PEG — 15% evidence | 3.4/20 RS sector -19.8% · RS bench -11.8% · 1Y -31.4%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 9.7 + 19.2 + 10.8 + 3.4 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Sigachi Industries LtdSIGACHI | 41.5/100Mixed-negative evidence79% evidence | BREAKING OUT | 9.0/35 Revenue -9.6% · PAT 100% · OPM change -5.2 pp 71% evidence | 7.2/25 ROCE 6.2% · OPM 13.6% 95% evidence | 8.4/20 P/E 64.5× · PEG — 50% evidence | 16.9/20 RS sector 6.2% · RS bench 38.7% · 1Y 20.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9 + 7.2 + 8.4 + 16.9 = 41.5 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Shree Ganesh Remedies LtdSGRL | 41.1/100Mixed-negative evidence76% evidence | 6.6/35 Revenue -8.8% · PAT -29.4% · OPM change -6.3 pp 95% evidence | 14.6/25 ROCE 14.1% · OPM 23.3% 76% evidence | 7.1/20 P/E 54.8× · PEG — 50% evidence | 12.8/20 RS sector 3.3% · RS bench 25.3% · 1Y 15.5%4 of 12 weeks ahead 70% evidence | |
| Exact sum: 6.6 + 14.6 + 7.1 + 12.8 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Oriental Aromatics LtdOAL | 36.0/100Mixed-negative evidence74% evidence | BREAKING OUT | 12.5/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 4.3/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 337× · PEG — 15% evidence | 10.5/20 RS sector -8.7% · RS bench 66.9% · 1Y 57.7%10 of 10 weeks ahead 70% evidence |
| Exact sum: 12.5 + 4.3 + 8.7 + 10.5 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Fairchem Organics LtdFAIRCHEMOR | 33.6/100Adverse evidence87% evidence | BREAKING OUT | 17.1/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 6.0/25 ROCE 3.3% · OPM 10% 95% evidence | 8.0/20 P/E 52× · PEG — 50% evidence | 2.5/20 RS sector -26.6% · RS bench -3.9% · 1Y -22.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 6 + 8 + 2.5 = 33.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Gem Aromatics LtdGEMAROMA | 24.4/100Adverse evidence65% evidence | ASLEEP | 1.8/35 Revenue -24.3% · PAT -80% · OPM change -13.6 pp 95% evidence | 6.4/25 ROCE 3.4% · OPM 3.3% 95% evidence | 8.5/20 P/E 772.2× · PEG — 15% evidence | 7.7/20 RS sector — · RS bench -10.4% · 1Y -39.3%5 of 10 weeks ahead 25% evidence |
| Exact sum: 1.8 + 6.4 + 8.5 + 7.7 = 24.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Sacheerome LtdSACHEEROME | 59.1/100Thin evidence · provisional41% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.3/25 ROCE 35.7% · OPM 23% 95% evidence | 9.7/20 P/E 40.1× · PEG — 15% evidence | 11.8/20 RS sector — · RS bench 46.9% · 1Y 155.5%9 of 10 weeks ahead 25% evidence |
| Exact sum: 17.3 + 20.3 + 9.7 + 11.8 = 59.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 36.7/100Thin evidence · provisional27% evidence | 11.8/35 Revenue — · PAT -68.2% · OPM change — 33% evidence | 4.9/25 ROCE -2150% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 11.8 + 4.9 + 10 + 10 = 36.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is BASF India Ltd's share price today?
BASF India Ltd trades at ₹3,662, −20.7% over the past year. The company is valued at ₹15,849 Cr. The stock sits at 32% of its 52-week range of ₹3,286–₹4,462, −4.8% versus its 200-day average. On the tape, the price is in a downtrend, 57 weeks in. — as of 11 September 2026.
What were BASF India Ltd's latest quarterly results?
BASF India Ltd reported revenue of ₹4,824 Cr and net profit of ₹360 Cr for the Jun 26 quarter. Revenue rose 24.5% and profit rose 162.8% year on year. Earnings per share were ₹83.24. The operating margin was 10.0%, 4.0 pp higher than a year earlier. — as of 11 September 2026.
What is BASF India Ltd's revenue?
BASF India Ltd reported revenue of ₹4,824 Cr in the Jun 26 quarter, +24.5% year on year. For the full FY26 fiscal year, revenue was ₹14,944 Cr (+1.1%). Over the last 20 years revenue compounded at 16.7% a year. — as of 11 September 2026.
What is BASF India Ltd's profit?
BASF India Ltd earned ₹360 Cr of net profit in the Jun 26 quarter, +162.8% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹420 Cr. The operating margin ran 10.0% in the latest quarter. — as of 11 September 2026.
What is BASF India Ltd's market cap?
BASF India Ltd's market capitalisation is ₹15,849 Cr at a share price of ₹3,662. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is BASF India Ltd's P/E ratio?
BASF India Ltd trades at a P/E of 25.7×, at the cheapest it has been in 6 years, against a long-run median of 50.8×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does BASF India Ltd pay a dividend?
Yes — BASF India Ltd's dividend payout was 26% of profit in FY26, and it recorded a payout in each of its last 9 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is BASF India Ltd overvalued?
On its own history, BASF India Ltd looks cheap: its P/E of 25.7× has been cheaper only 0% of the time in 6 years (long-run median 50.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is BASF India Ltd growing?
Yes — BASF India Ltd is growing: latest-quarter revenue +24.5% year on year, profit +162.8%, and the margin +4.0 pp at 10.0%. The 20-year compound rates are 16.7% (revenue) and 11.8% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is BASF India Ltd performing?
BASF India Ltd is in a downtrend, 57 weeks in. Its latest quarter's revenue rose 24.5% and profit rose 162.8% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is BASF India Ltd in?
Turning around — EPS growth swung from −42.2% at the trough to +62.4%, a 2-quarter improving streak, ROCE holding at 14.6%. The read comes from the last 12 quarters of growth (revenue growth +6.5% latest, profit growth +62.4% latest, eps growth +62.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is BASF India Ltd in an uptrend?
No — the price is in a downtrend (week 57 of stage 4), trading −4.8% versus its 200-day average and at 32% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is BASF India Ltd beating the market?
Not lately — on a trailing-13-week view BASF India Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-09-04), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +373% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.
Will BASF India Ltd's share price go up?
This page publishes no price forecast for BASF India Ltd. What it measures instead: the share price is ₹3,662, the price is in a downtrend 57 weeks in. Its P/E of 25.7× sits at the 0th percentile of its own 6-year range. — as of 11 September 2026.
Who owns BASF India Ltd?
Promoters hold 73.3% of BASF India Ltd, foreign institutions 5.2%, domestic institutions 6.3% and the public 15.2% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does BASF India Ltd have too much debt?
No — BASF India Ltd's debt-to-equity is 0.03, and operating profit covers the interest bill 35×. FY26 borrowings were ₹133 Cr against equity of ₹3,957 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is BASF India Ltd's capex?
BASF India Ltd spent ₹513 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹156 Cr, with ₹160 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is BASF India Ltd's cash flow?
BASF India Ltd consumed ₹110 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−266 Cr). Operating cash was negative while the company reported a profit of ₹420 Cr. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is BASF India Ltd's profit real cash?
Mostly — over the last 3 fiscal years, 73% of BASF India Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−110 Cr against reported profit of ₹420 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is BASF India Ltd in its business cycle?
BASF India Ltd's FY26 operating margin was 4.4%, against a 9-year band of 3.7%–13.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 10.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does BASF India Ltd's price assume?
At its price on 13 June 2026, BASF India Ltd was priced for profit growth of about 21.3% a year. Profit itself has compounded 11.8% a year over the past 20 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the BASF India Ltd story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is BASF India Ltd a stock worth studying right now?
This is not investment advice. The machine read: BASF India Ltd's stock has fallen further than its earnings. EPS fell 12.3% in a year while the price moved −20.7%. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!